Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Interest Coverage 24.61
SKBI's Interest Coverage is ranked higher than
53% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. SKBI: 24.61 )
Ranked among companies with meaningful Interest Coverage only.
SKBI' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 24.61
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
» SKBI's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SKBI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:INBP, OTCPK:ADIA, OTCPK:ENZB, OTCPK:ATHJF, NAS:BSPM, AMEX:CPHI, OTCPK:NNAB, OTCPK:ECTE, NAS:IMNP, OTCPK:CHEXF, OTCPK:NEVPF, NAS:PRPH, OTCPK:SUWN, OTCPK:INNV, NAS:ALQA, NAS:TNXP, NAS:ALIM, AMEX:AXN, OTCPK:PXSLY, OTCPK:BIOYF » details
Traded in other countries:GNJC.Germany,
Skystar Bio-Pharmaceutical Company is a holding company engaged in research, development, manufacturing and distribution of veterinary health care and medical care products in the People's Republic of China.

Skystar Bio-Pharmaceutical Company was incorporated in Nevada on September 24, 1998. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. All current operations of the Company are in the People's Republic of China. The Company's operations are carried out by Xi'an Tianxing Bio-Pharmaceutical Co., Limited, a PRC joint stock company that it controls through contractual arrangements originally between Skystar Cayman and Xi'an Tianxing. The Company has four major product lines, namely micro-organism products line; veterinary medicine line; feed additives line; bio-pharmaceutical veterinary vaccine line. Its micro-organism products line includes over 16 products; veterinary medicine line for poultry and livestock includes over 245 products; feed additives line includes over 16 products; and its bio-pharmaceutical veterinary vaccine line includes over 10 products. As of December 31, 2012, the Company had over 4,000 customers in 29 provinces in China, including 2,893 distributors and 1,122 direct customers. Of the 2,893 distributors, 360 are physical stores that have outer signage with its logo and sell products from its four product lines, known as franchise distributors. The Company competes with China Animal Husbandry Industry Co. Ltd. and Qilu Animal Health Production Co., Ltd. in China. In veterinary vaccine products, the Company competes with Xinjiang Tecon Animal Husbandry Bio-technology Co., Ltd. and Inner Mongolia Jinyu Group Stock Company.

Ratios

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $49.05
EPS (TTM) $ 1.36
Beta3.06
Short Percentage of Float1.08%
52-Week Range $0.13 - 2.30
Shares Outstanding (Mil)8.70

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec14
Revenue (Mil $)
EPS ($) 1.57
EPS w/o NRI ($) 1.57
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SKBI

Headlines

Articles On GuruFocus.com

More From Other Websites
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant,... Apr 28 2016
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Changes in Registrant's Certifying Accountant,... Apr 06 2016
Skystar Bio-Pharmaceutical Announces Final Delisting From Nasdaq and Continued Trading on OTC Pink... Feb 26 2016
SKYSTAR BIO-PHARMACEUTICAL CO Financials Dec 24 2015
Skystar Bio-Pharmaceutical Company Update Dec 22 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Dec 18 2015
Skystar Bio-Pharmaceutical Company Announces Delisting From NASDAQ Dec 18 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Nov 20 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter Nov 19 2015
Skystar Bio-Pharmaceutical Company Request to Stay Nasdaq Trading Suspension Granted Nov 06 2015
Skystar Bio-Pharmaceutical Company Receives Approval for T-Factor Animal Supplement Patent From... Oct 27 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Oct 23 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Notification Letter Oct 23 2015
Skystar Bio-Pharmaceutical Company Provides Investor Update Regarding Delay in Filing Form 10-K Oct 02 2015
Skystar Bio-Pharmaceutical Company Announces Receipt of Nasdaq Non-Compliance Letter Due to Delay in... Aug 25 2015
SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a... Aug 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)